NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Antimicrobial Resistance and Modernising Microbiology > Oxford team use DNA sequencing and patient data to halt infection outbreak

Oxford team use DNA sequencing and patient data to halt infection outbreak

3 October 2018 · Listed under Antimicrobial Resistance and Modernising Microbiology, Clinical Informatics and Big Data

Clinical and research teams at Oxford University Hospitals (OUH) NHS Foundation Trust, using infection prevention and control best practice, whole genome sequencing and electronic patient data, have halted an outbreak of a potentially deadly fungal pathogen after detecting that multi-use patient equipment was responsible.

The breakthrough at the John Radcliffe Hospital is significant as this is the first time an outbreak of Candida auris (C. auris) has been completely ended with a clear understanding of the cause.

The study, published on 3 October by the New England Journal of Medicine, was conducted by the Infection, Prevention and Control and Neurosciences Intensive Care Unit (ICU) teams from OUH, the University of Oxford’s Nuffield Department of Medicine, the Big Data Institute and the NIHR Health Protection Research Unit and Public Health England, and supported by the NIHR Oxford Biomedical Research Centre.

The lead investigator, Dr David Eyre, Research Fellow in Infectious Diseases at the Big Data Institute, said: “It is very pleasing that our research has led to the C. auris outbreak being stopped. There are a number of hospitals in the UK and around the world that have been unable to halt their outbreaks. Working out how it is transmitted should help to contain its spread worldwide.”

“Such is the nature of this pathogen that we must remain vigilant, and we’re delighted that, since we changed our approach as a result of our findings, we have had no further cases.”

C. auris is an emerging, multi-drug resistant fungal pathogen recently associated with outbreaks worldwide, often in intensive care units. In some patients, C. auris can enter the bloodstream and spread throughout the body, causing serious infection.

The researchers investigated a large C. auris outbreak at the John Radcliffe Hospital’s Neurosciences ICU between 2015 and 2017, during which 70 patients were identified as being colonised or infected with C. auris.

Using whole genome sequencing of patient and environmental isolates, combined with electronic health record data, they studied possible transmission routes, risk factors for colonisation and the molecular epidemiology of the outbreak.

Patients in Neurosciences ICU were regularly screened for C. auris, as were those on the adjacent Neurosciences ward. Samples were also taken from the environment, focusing on sampling high-touch areas and multi-use devices.

“We found that C. auris was rarely detected in the general environment; there was no trace of the organism on surfaces within the unit and only 1 out of 16 air samples was positive,” Dr Eyre explained.

“However, we did find C. auris on multi-use patient equipment, particularly temperature probes. There were close genetic matches between C. auris isolated from patients and from these thermometers. We found that having their temperature monitored with one of these probes was an important risk factor for acquiring C. auris. And unlike with pathogens like C. difficile, bed proximity did not appear to be a factor in transmission.

“So our research clearly showed that environmental survival appears to be key to Candida auris’s persistence and transmission in healthcare settings. This led to us implementing successful infection control measures to contain the outbreak – including removing multi-use skin surface thermometers from use,” he said.

Professor Derrick Crook, Director of National Infection Service at Public Health England and Antimicrobial Resistance Theme Lead at the NIHR Oxford Biomedical Research Centre, said: “This study will feed directly into healthcare guidelines regarding the use of multi-use equipment, and in particular the decontamination of this equipment in the event of future outbreaks.

“Although a relatively small number of patients in the Oxford study had clinically significant C. auris infections, such infections can have serious consequences for the kind of vulnerable patients admitted to intensive care units, particularly as C. auris is highly resistant to many anti-fungal agents. The action that was taken as a result of this research undoubtedly prevented more patients becoming colonised and infected.”

← UK-led study marks shift towards genetic era in tackling TB
Award-winning citizen science project tackling TB gets millionth classification →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre